Biomaterials seminars

Cryopreservation constrains manufacturing and clinical delivery of immune cells such as NK and T cells. DMSO protects against freezing but becomes toxic at physiological temperatures; associated infusion morbidity can require washing or divided dosing that diminishes therapeutic effectiveness. This talk presents an alternative in which reversible, cytocompatible hydrogels encapsulate cells before freezing without DMSO. The speaker examines evidence that encapsulation cushions osmotic stress, suppresses kinetic and phase transitions, and reduces injury caused by extracellular ice growth and fusion. The discussion covers recovery efficiency, function after thawing, control of biological stress responses, and the challenges of extending the approach to clinical-scale cell preservation.

Bowen Li explains how ionizable lipids are designed for lipid nanoparticles that deliver messenger RNA. The seminar covers combinatorial and machine-learning-guided design, four-component reactions for rapidly producing lipid libraries, and barcoded screening in living systems to identify formulations targeting organs and cells, including lungs, T cells and tumours. It then examines applications of AI-guided nanoparticle platforms to mRNA therapeutics. Li is an Associate Professor and Canada Research Chair at the University of Toronto's Leslie Dan Faculty of Pharmacy. Online via Zoom. Thursday 24 September 2026, 11:00–12:00 Eastern Daylight Time (America/New_York; UTC−4). Use Join via Zoom on Western University's event page. The stated audience includes researchers, students, alumni and the general public. Organized by Western University's Western Bioinformatics Research Seminar.

Living organisms have mastered the dynamic control of stresses within sheets to induce shape transformation and locomotion. For instance, the spatiotemporal pattern of action potential in a heart yields a dynamical stress field leading to shape changes and biological function. Such structures inspired the development of theoretical tools and responsive materials alike. Yet, present attempts to mimic their rich dynamics and phenomenology in autonomous synthetic matter are still very limited. In this talk, I will present several complementing innovations toward this goal: novel shaping mechanisms that were overlooked by previous research, new fabrication techniques for programmable matter via 4D printing of gel structures, and most prominently, the first autonomous shape morphing membranes. The dynamical control over the geometry of the material is a prevalent theme in all of these achievements. In particular, the latter system demonstrates localized deformations, induced by a pattern-forming chemical reaction, that prescribe the patterns of curvature, leading to global shape evolution. Together, these developments present a route for modeling and producing fully autonomous soft membranes mimicking some of the locomotive capabilities of living organisms.

Over the past 30 years bionic devices such as cochlear implants and pacemakers, have used a small number of metal electrodes to restore function and monitor activity in patients following disease or injury of excitable tissues. Growing interest in neurotechnologies, facilitated by ventures such as BrainGate, Neuralink and the European Human Brain Project, has increased public awareness of electrotherapeutics and led to both new applications for bioelectronics and a growing demand for less invasive devices with improved performance. Coupled with the rapid miniaturisation of electronic chips, bionic devices are now being developed to diagnose and treat a wide variety of neural and muscular disorders. Of particular interest is the area of high resolution devices that require smaller, more densely packed electrodes. Due to poor integration and communication with body tissue, conventional metallic electrodes cannot meet these size and spatial requirements. We have developed a range of polymer based electronic materials including conductive hydrogels (CHs), conductive elastomers (CEs) and living electrodes (LEs). These technologies provide synergy between low impedance charge transfer, reduced stiffness and an ability to be provide a biologically active interface. A range of electrode approaches are presented spanning wearables, implantables and drug delivery devices. This talk outlines the materials development and characterisation of both in vitro properties and translational in vivo performance. The challenges for translation and commercial uptake of novel technologies will also be discussed.

The human gut microbiome has emerged as a key player in the bidirectional communication of the gut-brain axis, affecting various aspects of homeostasis and pathophysiology. Until recently, the majority of studies that seek to explore the mechanisms underlying the microbiome-gut-brain axis cross-talk relied almost exclusively on animal models, and particularly gnotobiotic mice. Despite the great progress made with these models, various limitations, including ethical considerations and interspecies differences that limit the translatability of data to human systems, pushed researchers to seek for alternatives. Over the past decades, the field of in vitro modelling of tissues has experienced tremendous growth, thanks to advances in 3D cell biology, materials, science and bioengineering, pushing further the borders of our ability to more faithfully emulate the in vivo situation. Organ-on-chip technology and bioengineered tissues have emerged as highly promising alternatives to animal models for a wide range of applications. In this talk I’ll discuss our progress towards generating a complete platform of the human microbiota-gut-brain axis with integrated monitoring and sensing capabilities. Bringing together principles of materials science, tissue engineering, 3D cell biology and bioelectronics, we are building advanced models of the GI and the BBB /NVU, with real-time and label-free monitoring units adapted in the model architecture, towards a robust and more physiologically relevant human in vitro model, aiming to i) elucidate the role of microbiota in the gut-brain axis communication, ii) to study how diet and impaired microbiota profiles affect various (patho-)physiologies, and iii) to test personalised medicine approaches for disease modelling and drug testing.